Cero Therapeutics Holdings, INC

Cero Therapeutics Holdings, Inc. has entered into a second amended and restated promissory note, securing up to $2,085,200 in aggregate principal amount with SRX Global Inc.

CERo Therapeutics Holdings, Inc. has entered into an amended and restated convertible promissory note agreement for up to $1.41 million in total funding.

CERo Therapeutics Holdings, Inc. has entered into a $750,000 convertible promissory note agreement with SRX Health Solutions, Inc. to bolster its capital position.

CERo Therapeutics Holdings, Inc. has entered into a convertible promissory note agreement for up to $1 million in financing.

Cero Therapeutics Holdings, Inc. has issued a $350,000 convertible promissory note to Keystone Capital Partners, LLC, with a potential to draw up to $1,000,000.

CERO Therapeutics Holdings, Inc. announced a new $750,000 convertible note financing, a change in its independent auditor, and the appointment of Eric Francois to its board of directors.

CERO Therapeutics reported a significant increase in net loss for Q3 2025, faced Nasdaq delisting, and continues to rely on further capital raises to fund its early-stage clinical development.

CERO Therapeutics reported a significantly wider net loss for Q2 2025, driven by deemed dividends, while making progress in its AML and NSCLC/ovarian cancer clinical programs and securing additional financing.

CERO Therapeutics Holdings, Inc. announces its financial results for the quarter ended March 31, 2025, highlighting advancements in its lead drug candidate, CER-1236, and recent capital raising activities.

CERo Therapeutics Holdings has filed an amendment to its quarterly report for the period ended September 30, 2024, solely to include Inline Extensible Business Reporting Language (iXBRL) data tagging.

CERO Therapeutics reported its Q3 2024 financial results, highlighting increased operating expenses, a net loss, and ongoing efforts to address a clinical hold on its lead drug candidate, while also navigating Nasdaq listing compliance issues.

CERo Therapeutics Holdings, Inc. released its second quarter 2024 financial results, highlighting increased R&D spending, a net loss, and updates on its IND submission and Nasdaq listing compliance.

CERo Therapeutics Holdings, Inc. filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding directors, executive compensation, and governance.

CERo Therapeutics Holdings, Inc. outlines the material terms of its common and preferred stock, including various series of convertible preferred stock and outstanding warrants.

CERo Therapeutics Holdings files an amendment to its annual report to include information required by Part III of Form 10-K, covering details about directors, executive officers, compensation, and corporate governance.

CERo Therapeutics' 2024 10-K filing reveals ongoing losses, clinical trial advancements, and substantial doubt about its ability to continue as a going concern.

CERo Therapeutics Holdings, Inc. outlines the terms of its common and preferred stock, as well as various warrants, in a recent 10-K filing.

Director Eric Francois was granted 1,823,278 stock options in Cero Therapeutics Holdings, Inc. with a $0.055 strike price.

CERO Therapeutics Holdings Director Rolfe Lindsey was granted 690,900 stock options exercisable at $0.055 per share.

CERO Therapeutics Holdings Director Kathleen Laporte acquired 690,900 stock options at an exercise price of $0.055, effective January 7, 2026.

CERO Therapeutics Holdings, Inc.'s Chief Development Officer, Kristen Pierce, acquired 1,612,099 stock options exercisable at $0.055 per share.

CERO Therapeutics Holdings Director Shami Patel acquired 690,900 stock options at an exercise price of $0.055, exercisable from January 7, 2026.

CERO Therapeutics Holdings Director and 10% owner Brian G. Atwood acquired 1,612,099 stock options at an exercise price of $0.055 per share.

CERo Therapeutics Holdings, Inc. filed a supplement to its definitive proxy statement, clarifying the classification of proposals for its 2025 Special Meeting of Stockholders.

CERo Therapeutics Holdings, Inc. calls a special meeting to approve a reverse stock split, preferred stock issuance, and an increase in its equity incentive plan to address Nasdaq listing requirements and fund operations.

CERO Therapeutics is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split to maintain Nasdaq listing, approval of past share issuances, and an increase in the company's equity incentive plan.

CERO Therapeutics Holdings, Inc. is facing delisting from the Nasdaq Global Market due to its common stock trading at $0.10 or less for ten consecutive trading days.

CERo Therapeutics Holdings, Inc. has rescheduled its Autumn 2024 Special Meeting of Stockholders to November 11, 2024, to allow more time for stockholders to vote on key proposals including a reverse stock split and an increase to the equity incentive plan.

CERo Therapeutics is asking stockholders to approve a reverse stock split, the issuance of shares related to convertible preferred stock and warrants, and an increase in the company's equity incentive plan.

CERO Therapeutics Holdings, Inc. filed an S-1 registration statement for the resale of up to 729.6 million common shares by Keystone Capital Partners, LLC, following its delisting from Nasdaq to OTCQB.

CERo Therapeutics Holdings, Inc. filed an S-1 registration statement for the potential resale of up to 12.5 million common shares by Keystone Capital Partners, LLC, aiming to secure up to $25 million in gross proceeds to fund its innovative CER-T cell cancer therapies despite ongoing significant losses and going concern doubts.

CERo Therapeutics aims to raise capital to advance its clinical programs and for general corporate purposes through a public offering of common stock, pre-funded warrants, and common warrants.

CERo Therapeutics is offering up to 4 million shares of common stock, pre-funded warrants, and common warrants in a new offering.

CERo Therapeutics Holdings, Inc. is launching a public offering of common stock and warrants to raise capital while facing potential delisting from the Nasdaq.

CERo Therapeutics Holdings, Inc. has filed a prospectus for the potential resale of up to 210 million shares of its common stock by Keystone Capital Partners, LLC.

Brian G. Atwood and the Atwood-Edminster Trust have significantly increased their beneficial ownership in CERo Therapeutics Holdings, Inc. to 9.9%, following warrant exercises and new stock option grants, while remaining below the 9.99% beneficial ownership limitation.

An amended Schedule 13D filing reveals that key insiders, including Brian G. Atwood and Lynne H. Edminster, have increased their potential ownership in Cero Therapeutics Holdings, Inc. through a significant warrant purchase totaling nearly $1 million.

Isaiah Tibbs has reported beneficial ownership of 8.67% of CERO Therapeutics Holdings, Inc.'s Common Stock in a Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.99% in CERO Therapeutics Holdings, Inc.

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% passive beneficial ownership stake in CERO Therapeutics Holdings, Inc. as of March 31, 2025.